美罗华治疗32例弥漫型大B细胞性非何杰金氏淋巴瘤
The therapeutic effects of Rituximab on 32 diffuse large B cell non - Hodgkin lymphoma cases
作者：徐才刚,吴俣,陈心传,刘霆,贾永前
Author：
收稿日期： 年卷（期）页码：2004,(02):-147-149
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：非何杰金氏淋巴瘤;弥漫型大B细胞;美罗华;CHOP;CD20+
Key words：
基金项目：
中文摘要
目的 评价美罗华治疗弥漫型大B细胞性非何杰金氏淋巴瘤DLBCL的临床效果及不良反应。方法 用同期对照的前瞻性研究方法,将68例弥漫型大B细胞性NHL患者分为研究组(美罗华组)和对照组,前组32例用CHOP方案(环磷酰胺、阿霉素、长春新碱和强的松)联合美罗华治疗;后组36例单用CHOP方案。每4周循环1个疗程,3～6疗程后作评价。将两组患者按国际淋巴瘤预后因子指数(IPI)分为中低危组和高危组,分析其疗效与预后。全部患者6个疗程后停止治疗,随访观察生存情况。结果 美罗华组完全缓解率(CR)达56.3％,总有效率87.5%;对照组分别为13.9％、63.9%,两组疗效差异有统计学意义(P0.05)。美罗华组中中低危组的CR及部分缓解率(PR)分别为68.4％、26.3％,高危组分别为38.5%、38.5％(P
参考文献
[1] Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review [M]. 1973-1999． Bethesda,MD:National Cancer Institute, 2002
[2] Harris NL, Jaffe ES, Stein H, et al.A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group[J]. Blood, 1994,84:1361
[3] World health organization classification of tumours. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues[ M], Lyon: IARC Press,2001
[4] The International Non-Hodgkin' s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin' s lymphoma [J].N Engl J Med, 1993,329:987
[5] 张之南.血液病诊断及疗效标准[M].第2版.北京:科学出版社,1998． 349
[6] Reff ME, Garner K, Chambers KS, et al.Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20[ J]. Blood, 1994,83:435
[7] Taji H, Kagami Y, Okada Y, et al. Growth inhibition of CD2-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody[J]. Jpn J Cancer Res, 1998,89:748
[8] Stephan Mathas, Anke Rickers, Kurt Bommert, et al. Anti-CD20-and B-cell Receptor-mediated Apoptosis: Evidence for Shared In-tracellular Signaling Pathways[J] .Cancer Res,2000,60:7170
[9] Vose JM. Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin' s lymphoma[J]. J Clin Oncol, 2001,19:389
[10] Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma[J].N Engl J Med,2002,346:235
[11] Sonnen R.Schmidt WP.Kuse R,et al.Treatment results of aggressive B non-Hodgkin's lymphoma in advanced age considering comorbidi-ty[J]. Br J Haematol,2002,119(3) :634
【关闭】
